Who
Benjamin J. Zeskind
President and CEO
Company insider
Files Form 4 as: President and CEO, Immuneering.
In numbers
- Trades disclosed
- 29
- Buys
- 8
- Sells
- 0
- Bought
- $266K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Aug 2021
- Last trade
- 23 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 24 Jun 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K2,400 at $4.56 | filing |
| 23 Jun 2026filed 24 Jun 2026 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K2,400 at $4.56 | filing |
| 3 Feb 2026filed 5 Feb 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —688,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —688,000 at $0.00 | filing |
| 2 Jul 2025filed 3 Jul 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $25K7,015 at $3.53 | filing |
| 1 Jul 2025filed 3 Jul 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $10K2,985 at $3.38 | filing |
| 18 Jun 2025filed 20 Jun 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $50K21,000 at $2.39 | filing |
| 5 Feb 2025filed 7 Feb 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —480,000 at $0.00 | filing |
| 19 Mar 2024filed 19 Mar 2024 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $55K20,000 at $2.77 | filing |
| 8 Feb 2024filed 9 Feb 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —244,286 at $0.00 | filing |
| 8 Feb 2024filed 9 Feb 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,414 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —352,244 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,756 at $0.00 | filing |
| 22 Dec 2022filed 27 Dec 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 22 Dec 2022filed 27 Dec 2022 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code M | $7,5252,500 at $3.01 | filing |
| 12 Apr 2022filed 14 Apr 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 12 Apr 2022filed 14 Apr 2022 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code M | $6,0202,000 at $3.01 | filing |
| 23 Mar 2022filed 24 Mar 2022 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $24K3,000 at $8.02 | filing |
| 28 Feb 2022filed 1 Mar 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 28 Feb 2022filed 1 Mar 2022 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code M | $6,0202,000 at $3.01 | filing |
News
No headline names them, or the companies they trade most, lately.